Inhaled nitric oxide: Expanding indications beyond traditional boundaries
JHLT Open · 2026-11 · 14 · 100697
DOI: 10.1016/j.jhlto.2026.100697 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift JHLT Open, 2026-11. Verfasst von Elcin Omercikoglu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Mayo Clinic Jacksonville Campus, Jacksonville, FL. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Inhaled nitric oxide (iNO) is a selective pulmonary vasodilator that improves ventilation-perfusion matching with minimal effect on systemic blood pressure. Although the FDA approval is restricted to neonatal hypoxic respiratory failure associated with pulmonary hypertension, many clinicians now use iNO in adults with conditions where elevated pulmonary vascular resistance, right ventricular dysfunction threaten stability and hypoxic respiratory failure. This review examines both the mechanistic rationale and the available evidence for such off-label use. Examples range from acute RV failure in the ICU to perioperative support in cardiac surgery, heart and lung transplantation, and severe hypoxemic respiratory failure, including COVID-19-associated acute respiratory distress syndrome (ARDS). In these settings, iNO offers rapid afterload reduction and short-term improvement in oxygenation, but randomized trials are lacking and limited studies to date have failed to consistently show outcome benefits. Adverse effects such as methemoglobinemia, nitrogen dioxide toxicity, rebound pulmonary hypertension, and a potential increase in acute kidney injury risk in certain non-cardiac surgical populations. Additionally, cost considerations and other practical limitations must be weighed carefully. Overall, current evidence supports the use of iNO as an adjunctive therapy in carefully selected critically ill patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Mayo Clinic Jacksonville Campus, Jacksonville, FL.
- Apollo Hospitals Mumbai, Navi Mumbai, India.
Zitieren
APA
Omercikoglu, E., Bankar, P. L., Corro, R., Helgeson, S. A., Kiley, S. P., Patel, N. M., Patel, P., Baz, M. A., Guru, P. K., Martin, A., Saunders, H., Sanghavi, D. K., & Franco, P. M. (2026). Inhaled nitric oxide: Expanding indications beyond traditional boundaries. JHLT Open, 14, 100697. https://doi.org/10.1016/j.jhlto.2026.100697
Vancouver
Omercikoglu E, Bankar PL, Corro R, Helgeson SA, Kiley SP, Patel NM, et al. Inhaled nitric oxide: Expanding indications beyond traditional boundaries. JHLT Open. 2026;14:100697. doi:10.1016/j.jhlto.2026.100697
BibTeX
@article{Omercikoglu2026,
author = {Omercikoglu, Elcin and Bankar, Prashant L and Corro, Rosa and Helgeson, Scott A and Kiley, Sean P and Patel, Neal M and Patel, Parag and Baz, Maher A and Guru, Pramod K and Martin, Archer and Saunders, Hollie and Sanghavi, Devang K and Franco, Pablo Moreno},
title = {Inhaled nitric oxide: Expanding indications beyond traditional boundaries},
journal = {JHLT Open},
year = {2026},
volume = {14},
pages = {100697},
doi = {10.1016/j.jhlto.2026.100697}
}
EUVIMED